WARNING: This product is for research use only, not for human or veterinary use.
Hodoodo CAT#: H575959
CAS#: 99614-02-5 (free base)
Description: Ondansetron is used alone or with other medications to prevent nausea and vomiting caused by cancer drug treatment (chemotherapy) and radiation therapy. It is also used to prevent and treat nausea and vomiting after surgery. It works by blocking one of the body's natural substances (serotonin) that causes vomiting.
Hodoodo Cat#: H575959
Name: Ondansetron free base
CAS#: 99614-02-5 (free base)
Chemical Formula: C18H19N3O
Exact Mass: 293.15
Molecular Weight: 293.370
Elemental Analysis: C, 73.69; H, 6.53; N, 14.32; O, 5.45
Related CAS #: 99614-02-5 (free base) 99614-01-4 (HCl) 103639-04-9 (HCl hydrate),
Synonym: GR 38032; GR-38032; GR38032; GR 38032X; Ondansetron
IUPAC/Chemical Name: 4H-Carbazol-4-one, 1,2,3,9-tetrahydro-9-methyl-3-((2-methyl-1H-imidazol-1-yl)methyl)-
InChi Key: FELGMEQIXOGIFQ-UHFFFAOYSA-N
InChi Code: InChI=1S/C18H19N3O/c1-12-19-9-10-21(12)11-13-7-8-16-17(18(13)22)14-5-3-4-6-15(14)20(16)2/h3-6,9-10,13H,7-8,11H2,1-2H3
SMILES Code: O=C1C(CN2C=CN=C2C)CCC(N3C)=C1C4=C3C=CC=C4
Appearance: Solid powder
Purity: >98% (or refer to the Certificate of Analysis)
Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility: Soluble in DMSO
Shelf Life: >2 years if stored properly
Drug Formulation: This drug may be formulated in DMSO
Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code: 2934.99.9001
More Info: The 5-HT3 receptors are present both peripherally on vagal nerve terminals and centrally in the chemoreceptor trigger zone of the area postrema in the medulla. Serotonin is released by the enterochromaffin cells of the small intestine in response to chemotherapeutic agents and may stimulate vagal afferents (via 5-HT3 receptors) to initiate the vomiting reflex. It is thought that ondansetron's antiemetic action is mediated mostly via antagonism of vagal afferents with a minor contribution from antagonism of central receptors.
| Biological target: | |
| In vitro activity: | |
| In vivo activity: |
The following data is based on the product molecular weight 293.37 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
| Concentration / Solvent Volume / Mass | 1 mg | 5 mg | 10 mg |
|---|---|---|---|
| 1 mM | 1.15 mL | 5.76 mL | 11.51 mL |
| 5 mM | 0.23 mL | 1.15 mL | 2.3 mL |
| 10 mM | 0.12 mL | 0.58 mL | 1.15 mL |
| 50 mM | 0.02 mL | 0.12 mL | 0.23 mL |
| Formulation protocol: | |
| In vitro protocol: | |
| In vivo protocol: |
1: Billio A, Morello E, Clarke MJ. Serotonin receptor antagonists for highly emetogenic chemotherapy in adults. Cochrane Database Syst Rev. 2010 Jan 20;(1):CD006272. Review. PubMed PMID: 20091591.
2: Frost F, Dailler F, Duflo F. [Ondansetron: a meta-analysis on its efficacy to prevent postoperative nausea and vomiting after craniotomy in adults and children]. Ann Fr Anesth Reanim. 2010 Jan;29(1):19-24. Epub 2010 Jan 15. French. PubMed PMID: 20080017.
3: Pikó B, Bassam A. [Treatment of tumor therapy-induced nausea and vomiting]. Magy Onkol. 2009 Mar;53(1):39-45. Review. Hungarian. PubMed PMID: 19318325.
4: Saito M, Aogi K, Sekine I, Yoshizawa H, Yanagita Y, Sakai H, Inoue K, Kitagawa C, Ogura T, Mitsuhashi S. Palonosetron plus dexamethasone versus granisetron plus dexamethasone for prevention of nausea and vomiting during chemotherapy: a double-blind, double-dummy, randomised, comparative phase III trial. Lancet Oncol. 2009 Feb;10(2):115-24. Epub 2009 Jan 8. Erratum in: Lancet Oncol. 2010 Mar;11(3)226. PubMed PMID: 19135415.
5: Reddy GK, Gralla RJ, Hesketh PJ. Novel neurokinin-1 antagonists as antiemetics for the treatment of chemotherapy-induced emesis. Support Cancer Ther. 2006 Apr 1;3(3):140-2. PubMed PMID: 18632487.
